Current partner codePEPTIDESDE
NCT07409493·Not applicable·INTERVENTIONAL

IVF Outcomes With Time-Lapse Culture: Comparison Between PPOS and GnRH Antagonist Protocols

Status

Recruiting

Phase

Not applicable

Enrollment

148

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

The goal of this clinical trial is to compare two ovarian stimulation protocols used in in vitro fertilization (IVF): the fixed Progestin-Primed Ovarian Stimulation (PPOS) protocol and the GnRH Antagonist protocol. The study will evaluate IVF outcomes and embryo development patterns using time-lapse embryo monitoring technology. The main questions the study aims to answer are: * Does the fixed - PPOS protocol achieve similar numbers of mature eggs, good-quality embryos, and clinical outcomes compared to the GnRH Antagonist protocol? * Are there differences in embryo development patterns (morphokinetics) between the two protocols when monitored by time-lapse imaging? * How does embryo quality (KIDScore) compare between the two protocols? Study Design: Researchers will randomly assign 148 women undergoing IVF to two groups: * PPOS group (n=74): Will receive FSH injections (oral Duphaston 20mg daily) starting from day 2-3 of the menstrual cycle * GnRH Antagonist group (n=74): Will receive FSH injections (Orgalutran 0.25mg injections) when follicles reach ≥14mm Participants will: * Undergo controlled ovarian stimulation with their assigned protocol for approximately 10-12 days * Have regular ultrasound monitoring and blood tests to track follicle development * Undergo egg retrieval procedure when follicles are mature * Have all embryos cultured in the EmbryoScope time-lapse incubator with continuous monitoring * Have embryos frozen on Day 5/6 for future transfer Study Location: Department of Assisted Reproduction and Andrology, Hanoi Obstetrics and Gynecology Hospital Study Duration: January 2026 - June 2028

Interventions

Treatment arms and agents.

DRUG

Progestin-Primed Ovarian Stimulation

Ovarian stimulation using progestin-primed ovarian stimulation (PPOS) protocol. Patients receive recombinant FSH starting from day 2-3 of menstrual cycle, concomitantly with oral Dydrogesterone 20mg daily to prevent premature LH surge. All embryos are cultured using time-lapse technology and cryopreserved for subsequent frozen embryo transfer.

DRUG

Antagonist protocol for IVF

Ovarian stimulation using GnRH antagonist protocol. Patients receive recombinant FSH starting from day 2-3 of menstrual cycle. GnRH antagonist is added when leading follicle reaches 12-14mm diameter to prevent premature LH surge. All embryos are cultured using time-lapse technology and cryopreserved for subsequent frozen embryo transfer.

Timeline

From registration to results.

  1. First posted

    Feb 13, 2026

  2. Study start

    Jan 21, 2026

  3. Primary completion

    Jun 2028

  4. Study completion

    Oct 2028

  5. Results posted

    Not reported

  6. Registry updated

    Feb 13, 2026

Outcomes

What the study measures.

Primary outcomes

Blastocyst formation rate

Time frame · Day 5 to Day 6 after oocyte retrieval

Number of high-quality blastocysts (grade ≥ 3BB) obtained per cycle

Secondary outcomes

Embryo morphokinetic development

Time frame · Day 2 to day 5 after oocyte retrieval

Compare the embryomorphokinetic milestones evaluated using the time-lapse evaluation system (EmbryoScope+ Vitrolife).

Eligibility

Who can take part.

Minimum age
20 Years
Maximum age
45 Years
Sex
FEMALE
Healthy volunteers
No

Inclusion Criteria: * Women aged 20-45 years * Indicated for in vitro fertilization (IVF) treatment * Planned freeze-all embryo strategy * Voluntary participation in research. Exclusion Criteria: * Systemic diseases * Use of hormonal medications within 3 months prior to enrollment * Oocyte donation cycles * Unwilling or unable to participate in research

Study locations

1 registered sites.

Vietnam. Showing up to 24 locations stored in the fast local snapshot.

Hanoi Obstetrics and Gynecology Hospital

Hanoi, Vietnam

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Ganirelix.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.